Logo image of BGBIO.OL

BERGENBIO ASA (BGBIO.OL) Stock Price, Forecast & Analysis

Europe - Euronext Oslo - OSL:BGBIO - NO0013251173 - Common Stock

1.198 NOK
+0.07 (+5.83%)
Last: 10/30/2025, 3:44:05 PM

BGBIO.OL Key Statistics, Chart & Performance

Key Statistics
Market Cap46.83M
Revenue(TTM)848.00K
Net Income(TTM)-139.28M
Shares39.09M
Float23.10M
52 Week High15.67
52 Week Low1.02
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-3.75
PEN/A
Fwd PEN/A
Earnings (Next)11-11
IPO2017-04-07
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
BGBIO.OL short term performance overview.The bars show the price performance of BGBIO.OL in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30

BGBIO.OL long term performance overview.The bars show the price performance of BGBIO.OL in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 100 200 300 400

The current stock price of BGBIO.OL is 1.198 NOK. In the past month the price increased by 0.5%. In the past year, price decreased by -84.53%.

BERGENBIO ASA / BGBIO Daily stock chart

BGBIO.OL Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to BGBIO.OL. When comparing the yearly performance of all stocks, BGBIO.OL is a bad performer in the overall market: 96.79% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

BGBIO.OL Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to BGBIO.OL. While BGBIO.OL seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BGBIO.OL Financial Highlights

Over the last trailing twelve months BGBIO.OL reported a non-GAAP Earnings per Share(EPS) of -3.75. The EPS increased by 70.32% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -160.55%
ROE -207.87%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%0.07%
Sales Q2Q%N/A
EPS 1Y (TTM)70.32%
Revenue 1Y (TTM)139.55%

BGBIO.OL Forecast & Estimates

7 analysts have analysed BGBIO.OL and the average price target is 5.1 NOK. This implies a price increase of 325.71% is expected in the next year compared to the current price of 1.198.

For the next year, analysts expect an EPS growth of 17.6% and a revenue growth -100% for BGBIO.OL


Analysts
Analysts40
Price Target5.1 (325.71%)
EPS Next Y17.6%
Revenue Next Year-100%

BGBIO.OL Ownership

Ownership
Inst OwnersN/A
Ins OwnersN/A
Short Float %N/A
Short RatioN/A

BGBIO.OL Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
1AE.DE ARGENX SE 65.33 43.00B
ARGX.BR ARGENX SE 64.88 42.70B
22UA.DE BIONTECH SE-ADR N/A 22.64B
2X1.DE ABIVAX SA N/A 8.09B
ABVX.PA ABIVAX SA N/A 7.97B
GXE.DE GALAPAGOS NV N/A 1.94B
GLPG.AS GALAPAGOS NV N/A 1.92B
IVA.PA INVENTIVA SA N/A 1.08B
6IV.DE INVENTIVA SA N/A 962.73M
NANO.PA NANOBIOTIX N/A 891.02M
5CV.DE CUREVAC NV 6.71 876.36M
PHIL.MI PHILOGEN SPA 19.12 637.43M

Related stock screener links

About BGBIO.OL

Company Profile

BGBIO logo image BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Bergen, Hordaland and currently employs 7 full-time employees. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) which is a tyrosine kinase target that mediates aggressive disease. Under normal healthy physiological conditions, there is low expression of AXL. However, in aggressive diseases, such as cancer and severe respiratory infections, AXL signaling is upregulated in response to hypoxia, inflammation, cellular stress and drug treatment. The firm's flagship product is BGB324, is a selective, potent and orally bio-available small molecule AXL inhibitor in Phase II clinical trials in cancer indications and COVID-19. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK.

Company Info

BERGENBIO ASA

Nygardsgaten 114

Bergen HORDALAND NO

Employees: 14

BGBIO Company Website

BGBIO Investor Relations

Phone: 4755961159

BERGENBIO ASA / BGBIO.OL FAQ

Can you describe the business of BERGENBIO ASA?

BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Bergen, Hordaland and currently employs 7 full-time employees. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) which is a tyrosine kinase target that mediates aggressive disease. Under normal healthy physiological conditions, there is low expression of AXL. However, in aggressive diseases, such as cancer and severe respiratory infections, AXL signaling is upregulated in response to hypoxia, inflammation, cellular stress and drug treatment. The firm's flagship product is BGB324, is a selective, potent and orally bio-available small molecule AXL inhibitor in Phase II clinical trials in cancer indications and COVID-19. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK.


What is the stock price of BERGENBIO ASA today?

The current stock price of BGBIO.OL is 1.198 NOK. The price increased by 5.83% in the last trading session.


What is the dividend status of BERGENBIO ASA?

BGBIO.OL does not pay a dividend.


What is the ChartMill technical and fundamental rating of BGBIO stock?

BGBIO.OL has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Can you provide the number of employees for BERGENBIO ASA?

BERGENBIO ASA (BGBIO.OL) currently has 14 employees.


What is the market capitalization of BGBIO stock?

BERGENBIO ASA (BGBIO.OL) has a market capitalization of 46.83M NOK. This makes BGBIO.OL a Nano Cap stock.